Lawsuit against Bristol Myers over delayed cancer drug is revived
A U.S. appeals court revived a $6.7 billion lawsuit accusing Bristol Myers Squibb of delaying FDA approval for three drugs tied to Celgene contingent value rights, including Breyanzi. The 2nd Circuit said a lower court erred in dismissing the case and that UMB Bank could represent shareholders as trustee. Bristol Myers denied wrongdoing.
How this was made
The 30-second read
Why it matters
The appeals court said the dismissal was erroneous and revived the $6.7B case, keeping legal overhang active and potentially increasing expected litigation costs and settlement risk.
Market read
A federal appeals court reinstated a major pharma shareholder lawsuit, renewing uncertainty around potential damages tied to FDA approval timing.
What to watch
Traders should monitor whether the ruling changes the scope of claims in the related UMB lawsuit and any disclosures about CVR delisting/enforcement mechanics.
Background
Bristol Myers bought Celgene in 2019; Celgene CVR holders alleged delayed FDA approvals triggered large cash payouts.
Ticker impact
An appeals court revived a $6.7B lawsuit accusing Bristol Myers of delaying FDA approval for Breyanzi and other drugs tied to CVR payouts.
Near-term downside bias on legal-risk headlines; magnitude depends on settlement/ultimate merits and any related CVR exposure.
The decision reinstates claims and can extend uncertainty around damages and governance of approval timelines, but the article does not quantify updated damages or immediate financial guidance impact.
Market effects
Highlights litigation risk around FDA approval timing and contingent payout structures for large pharma deals.
Primarily US legal/regulatory risk sentiment for large-cap pharma.
Limited direct global read-across, but reinforces US-centric enforcement around drug approval timelines.
Counterpoint
Even with revival, Bristol Myers may still prevail on merits; reinstatement does not equal liability or damages.
Key entities
- companyBristol Myers Squibb
Defendant in a revived $6.7B lawsuit alleging delayed FDA approvals tied to Celgene CVR payouts.
- companyUMB Bank
Appointed trustee for Celgene shareholders; appeals court held it had standing to sue despite an appointment error.
- drugBreyanzi
Bristol Myers cancer treatment referenced as one of the delayed-approval drugs tied to CVR deadlines.
- companyCelgene
Acquired by Bristol Myers in 2019; CVR holders are the plaintiffs in the dispute.
